# Ipilimumab With Carboplatin and Paclitaxel in Patients With Unresectable Stage III and Stage IV Melanoma

> **NCT01676649** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Jewish General Hospital** · enrollment: 30 (actual)

## Conditions studied

- Untreated Stage III Melanoma or Stage IV Melanoma

## Interventions

- **BIOLOGICAL:** Ipilimumab
- **DRUG:** Carboplatin
- **DRUG:** Paclitaxel

## Key facts

- **NCT ID:** NCT01676649
- **Lead sponsor:** Jewish General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2012-11
- **Primary completion:** 2017-02
- **Final completion:** 2026-05
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2021-02-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01676649

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01676649, "Ipilimumab With Carboplatin and Paclitaxel in Patients With Unresectable Stage III and Stage IV Melanoma". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01676649. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*